Human Molecular Genetics, 2003, Vol. 12, No. 14 1651-1659
DOI: 10.1093/hmg/ddg188
© 2003 Oxford University Press
Heterozygous mutations in BBS1, BBS2 and BBS6 have a potential epistatic effect on BardetBiedl patients with two mutations at a second BBS locus
1Institute of Genetic Medicine, Johns Hopkins University, 600 North Wolfe Street, Baltimore, MD 21287, USA, 2Department of Molecular Biology and Biochemistry, Simon Fraser University, Burnaby, BC, Canada V5A 1S6, 3Molecular Medicine Unit, Institute of Child Health, University College London, London WC1N 1EH, UK, 4Departments of Molecular and Human Genetics, Ophthalmology, Pediatrics, and Medicine, Baylor College of Medicine, One Baylor Plaza, Houston TX 77030, USA, 5The Clinical Genetics Service, Bolzano General Hospital, Bolzano 39100, Italy and 6Wilmer Eye Institute, Johns Hopkins University, 600 North Wolfe Street, Baltimore, MD 21287, USA
Received March 3, 2003; Accepted May 19, 2003
BardetBiedl syndrome (BBS) is a pleiotropic genetic disorder with substantial inter- and intrafamilial variability, that also exhibits remarkable genetic heterogeneity, with seven mapped BBS loci in the human genome. Recent data have demonstrated that BBS may be inherited either as a simple Mendelian recessive or as an oligogenic trait, since mutations at two loci are sometimes required for pathogenesis. This observation suggests that genetic interactions between the different BBS loci may modulate the phenotype, thus contributing to the clinical variability of BBS. We present three families with two mutations in either BBS1 or BBS2, in which some but not all patients carry a third mutation in BBS1, BBS2 or the putative chaperonin BBS6. In each example, the presence of three mutant alleles correlates with a more severe phenotype. For one of the missense alleles, we also demonstrate that the introduction of the mutation in mammalian cells causes a dramatic mislocalization of the protein compared with the wild-type. These data suggest that triallelic mutations are not always necessary for disease manifestation, but might potentiate a phenotype that is caused by two recessive mutations at an independent locus, thus introducing an additional layer of complexity on the genetic modeling of oligogenicity.
* To whom correspondence should be addressed at: Institute of Genetic Medicine, 2-127 Jefferson Street Building, Johns Hopkins University, 600 North Wolfe Street, Baltimore, MD 21287, USA. Tel: +1 4105026660; Fax: +1 4105027544; Email: katsanis{at}jhmi.edu
![]()
CiteULike
Connotea
Del.icio.us What's this?
This article has been cited by other articles:
![]() |
Q. Liu, A. Saveliev, and E. A. Pierce The Severity of Retinal Degeneration in Rp1h Gene-Targeted Mice Is Dependent on Genetic Background Invest. Ophthalmol. Vis. Sci., April 1, 2009; 50(4): 1566 - 1574. [Abstract] [Full Text] [PDF] |
||||
![]() |
T D. Hjortshoj, K Gronskov, K Brondum-Nielsen, and T Rosenberg A novel founder BBS1 mutation explains a unique high prevalence of Bardet-Biedl syndrome in the Faroe Islands Br J Ophthalmol, March 1, 2009; 93(3): 409 - 413. [Abstract] [Full Text] [PDF] |
||||
![]() |
F. Hildebrandt, M. Attanasio, and E. Otto Nephronophthisis: Disease Mechanisms of a Ciliopathy J. Am. Soc. Nephrol., January 1, 2009; 20(1): 23 - 35. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. K. Tayeh, H.-J. Yen, J. S. Beck, C. C. Searby, T. A. Westfall, H. Griesbach, V. C. Sheffield, and D. C. Slusarski Genetic interaction between Bardet-Biedl syndrome genes and implications for limb patterning Hum. Mol. Genet., July 1, 2008; 17(13): 1956 - 1967. [Abstract] [Full Text] [PDF] |
||||
![]() |
M Adams, U M Smith, C V Logan, and C A Johnson Recent advances in the molecular pathology, cell biology and genetics of ciliopathies J. Med. Genet., May 1, 2008; 45(5): 257 - 267. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Hoefele, M. T.F. Wolf, J. F. O'Toole, E. A. Otto, U. Schultheiss, G. Deschenes, M. Attanasio, B. Utsch, C. Antignac, and F. Hildebrandt Evidence of Oligogenic Inheritance in Nephronophthisis J. Am. Soc. Nephrol., October 1, 2007; 18(10): 2789 - 2795. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. A. Azari, T. S. Aleman, A. V. Cideciyan, S. B. Schwartz, E. A. M. Windsor, A. Sumaroka, A. Y. Cheung, J. D. Steinberg, A. J. Roman, E. M. Stone, et al. Retinal Disease Expression in Bardet-Biedl Syndrome-1 (BBS1) Is a Spectrum from Maculopathy to Retina-Wide Degeneration Invest. Ophthalmol. Vis. Sci., November 1, 2006; 47(11): 5004 - 5010. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. S. Woolf Renal Hypoplasia and Dysplasia: Starting to Put the Puzzle Together J. Am. Soc. Nephrol., October 1, 2006; 17(10): 2647 - 2649. [Full Text] [PDF] |
||||
![]() |
P. Hanlon, W. A. Lorenz, Z. Shao, J. M. Harper, A. T. Galecki, R. A. Miller, and D. T. Burke Three-locus and four-locus QTL interactions influence mouse insulin-like growth factor-I Physiol Genomics, September 14, 2006; 26(1): 46 - 54. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. Smaoui, M. Chaabouni, Y. V. Sergeev, H. Kallel, S. Li, N. Mahfoudh, F. Maazoul, H. Kammoun, N. Gandoura, A. Bouaziz, et al. Screening of the Eight BBS Genes in Tunisian Families: No Evidence of Triallelism. Invest. Ophthalmol. Vis. Sci., August 1, 2006; 47(8): 3487 - 3495. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. N. A. Mandal, J. R. Heckenlively, T. Burch, L. Chen, V. Vasireddy, R. K. Koenekoop, P. A. Sieving, and R. Ayyagari Sequencing Arrays for Screening Multiple Genes Associated with Early-Onset Human Retinal Degenerations on a High-Throughput Platform Invest. Ophthalmol. Vis. Sci., September 1, 2005; 46(9): 3355 - 3362. [Abstract] [Full Text] [PDF] |
||||
![]() |
J R Porter and T G Barrett Acquired non-type 1 diabetes in childhood: subtypes, diagnosis, and management Arch. Dis. Child., December 1, 2004; 89(12): 1138 - 1144. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. Katsanis The oligogenic properties of Bardet-Biedl syndrome Hum. Mol. Genet., April 1, 2004; 13(90001): R65 - 71. [Abstract] [Full Text] [PDF] |
||||






